DWT
REGN icon

Dorsey & Whitney Trust’s Regeneron Pharmaceuticals REGN Stock Holding History

Dorsey & Whitney Trust’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$425K Sell
551
-2
-0.4% -$1.53K 0.02% 475
2025
Q4 		$427K Buy
553
+67
+14% +$45.5K 0.02% 468
2025
Q3 		$273K Sell
486
-20
-4% -$11.3K 0.01% 565
2025
Q2 		$266K Buy
506
+145
+40% +$80.9K 0.01% 568
2025
Q1 		$229K Sell
361
-275
-43% -$189K 0.01% 601
2024
Q4 		$453K Sell
636
-84
-12% -$70.5K 0.03% 418
2024
Q3 		$757K Buy
720
+271
+60% +$302K 0.04% 314
2024
Q2 		$472K Sell
449
-138
-24% -$134K 0.03% 368
2024
Q1 		$565K Buy
587
+124
+27% +$118K 0.04% 335
2023
Q4 		$407K Sell
463
-41
-8% -$33.8K 0.03% 382
2023
Q3 		$415K Buy
504
+7
+1% +$5.5K 0.04% 350
2023
Q2 		$357K Buy
497
+206
+71% +$159K 0.03% 395
2023
Q1 		$239K Buy
291
+8
+3% +$6.03K 0.02% 485
2022
Q4 		$204K Buy
+283
New +$209K 0.02% 528

Other funds holding REGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Dorsey & Whitney Trust's REGN Position: Q1 2026 in Review

Dorsey & Whitney Trust reduced its Regeneron Pharmaceuticals (REGN) stake by 0.36% in Q1 2026, selling an estimated $1.53K and leaving 551 shares worth $425K. The position accounts for 0.02% of the portfolio, ranked #475.

Dorsey & Whitney Trust first reported a position in REGN in Q4 2022 and has held it in 14 quarters since. The position peaked at $757K in Q3 2024. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • Dorsey & Whitney Trust held 551 shares of Regeneron Pharmaceuticals worth $425K as of Q1 2026.
  • Dorsey & Whitney Trust sold 2 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $1.53K.
  • Regeneron Pharmaceuticals made up 0.02% of Dorsey & Whitney Trust's portfolio in Q1 2026, its #475 holding.
  • Dorsey & Whitney Trust first reported a position in Regeneron Pharmaceuticals in Q4 2022 and has held it in 14 quarters since.
  • Dorsey & Whitney Trust's Regeneron Pharmaceuticals position peaked at $757K in Q3 2024.
  • 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Dorsey & Whitney Trust's 13F filing for Q1 2026, filed 14 May 2026.